## Abdominal Aortic Aneurysm Guideline Committee – development

**Date:** 18/12/2017 – 19/12/2017

Location: NICE offices, London

Minutes:

Final



Committee members present:		
	Day 1	Day 2
Andrew Bradbury (AB) – Chair	Present for all	Present for all items except item 3
Alun Huw Davies (AD)	Present for all	Present for all items except item 3
Jugdeep Dhesi (JD)	Present for all	Present from item 3
Chris Hammond (CH) – Chair for item 3	Present for all	Present for all
Mark Hampshire (MH)	Present for all	Present for all
Jaqui Lindridge (JL)	Present for all	Present for all
Adam Pichel (AP)	Present for all	Present for all
Les Ruffell (LR)	Present for all	Present for all
Matthew Slater (MS)	Present for all	Present for all
Alan Huw Smith (AS)	Present for all	Present for all
Sammer Tang (ST)	Apologies	Present for all
Hazel Trender (HT)	Present from partway through item 2	Present for all
Noel Wilson (NW)	Present for all	Present for all items except item 3 until partway through item 5

In attendance:		
	Day 1	Day 2
Jamie Elvidge (JE)	Present for all	Present for all
Senior Analyst – HE		
James Hall (JH)	Present for all	Present from item 3
Senior Medical Editor		
Thomas Jarrett (TK)	Present for all	Apologies
Technical Analyst		
Justine Karpusheff (JK)	Present for all	Apologies
Guidelines Commissioning Manager		
Caroline Mulvihill (CM)	Present for all	Present for all
Technical Adviser		
Adam O'Keefe (AO)	Present for all	Present for all

Project Manager		
Gabriel Rogers (GR)	Present for all	Present for all
Technical Adviser (HE)		
Jeffrey Tabiri-Essuman (JT)	Present for all	Present for all
Technical Analyst		
Sue Spiers (SS)	Present for all	Present for all
Associate Director		

Observer:		
Aedin McSloy	Technical Analyst, NICE	Present for all on both days

Apologies:	
Ivan Benett – Committee member	
Karen Jellett – Committee member	
Tamsin Ribbons – Committee member	
Sarah Glover – NICE Information Specialist	
Lisa Stone – NICE Medicines Adviser	

## Day 1 Monday 18 December 2017:

## 1. Welcome, apologies, minutes of the last meeting, declarations of interest

## **Welcome**

The Chair welcomed the Committee members and attendees to day one of the fourteenth meeting of the abdominal aortic aneurysm guideline committee.

#### **Apologies**

Apologies for the meeting were received as detailed above.

#### **Objectives**

The Chair outlined the main objectives of the day, which included the presentation of additional Health Economic analysis supporting Review Question 12, followed by agreement of the draft recommendations; then the evidence review on Review Question 31 and an update on development of the Health Economic model in the afternoon.

#### Minutes of the last meeting

The minutes were agreed as an accurate record of the previous meeting.

#### **Declarations of interest**

Each committee member was asked to declare any new conflicts since the previous meeting. No new interests were declared.

The Chair reminded the committee that evidence supporting Review Question 12 had been presented at the previous meeting. The Chair advised the committee that due to conflicts of interest declared by NW and AD in relation to their private practice in the area of AAA surgery that these committee members would be required to leave the room when the draft recommendations on this question were discussed and agreed. Whilst not currently conflicted but due to the potential for the Chair to undertake private practice in this area in the future AB informed the committee that he would also leave the room for this part of the meeting. CH agreed to Chair the meeting during this item.

Having reviewed the historical declaration of interests table, the Chair declared that the remainder of the committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Additional Health Economic analysis supporting Review Question 12: What is the effectiveness of EVAR compared to open repair surgery in reducing morbidity and mortality in people with unruptured abdominal aortic aneurysms?

JE presented the results of additional analysis performed at the committee's request, on the Health Economic evidence supporting Review Question 12, building on the work presented at the previous meeting.

## 3. Ratification of recommendations for Review Question 12

The Chair, NW and AD left the room at the beginning of this section and CH took over as Chair.

The remaining committee members revisited the evidence and reviewed the evidence statements supporting Review Question12 before agreeing four draft recommendations.

#### 4. Health Economic Update – Review Questions 4 & 7

The Chair, NW and AHD re-joined the meeting.

JE and GR presented the committee with an update on development of the proposed economic model informing Review Questions 4 and 7 and sought the views of the committee on the work they had done on updating the parameters and on some preliminary outputs.

## 5. Review Question 31: How should complications be managed if they do arise?

TJ introduced himself as a new Technical Analyst supporting development of this guideline. TJ recapped the search protocols and presented the clinical evidence supporting Review Question 31. There was no economic evidence identified for this question.

The committee considered the evidence presented and drafted 3 recommendations but requested

it revisit these recommendations at the next meeting.

## 6. Next steps

The Chair thanked the committee for their input and confirmed day 2 would commence at 9am.

## Day 2 Tuesday 19 December 2017:

## 1. Welcome, apologies, declarations of interest

## **Introduction**

The Chair welcomed the Committee members and attendees to day two of the fourteenth meeting of the abdominal aortic aneurysm guideline committee.

## <u>Apologies</u>

Apologies for the meeting were received as detailed above.

## **Objectives**

The Chair outlined the main objectives of the day, which included the presentation of evidence reviews for review questions 17, 19, 21 and 25.

#### **Declarations of interest**

Each committee member was asked to declare any new conflicts. No new interests were declared.

The Chair confirmed that the committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Review Question 17: Within what time period should people with suspected ruptured or symptomatic unruptured abdominal aortic aneurysms be transferred from a nonspecialist setting to a specialist vascular unit?

JT informed the committee that no relevant evidence had been identified and provided an explanation for the reasons studies had been excluded. No relevant health economic evidence had been identified.

The committee acknowledged the lack of evidence in this area but discussed their own current clinical practice and drafted two recommendations based on their experience and expertise.

3. Review Question 25: What is the most effective approach in preventing abdominal compartment syndrome during surgical repair of a ruptured abdominal aortic aneurysm?

JT recapped the search protocols and presented the clinical evidence supporting Review Question

25 for the committee's consideration.

The committee considered the evidence presented and drafted two recommendations.

4. Review Question 19: Does permissive hypotension improve a person's chance of survival or improve the stability of their condition in the transfer of people with ruptured or symptomatic abdominal aortic aneurysms to a specialist vascular unit?

JT recapped the search protocols and presented the clinical evidence supporting Review Question 19 for the committee's consideration.

The committee considered the evidence presented and drafted one recommendation.

5. Review Question 21: Which signs, symptoms, risk factors (or combinations of these) and assessment tools predict survival in people with ruptured abdominal aortic aneurysms?

JT recapped the search protocols and presented the clinical evidence supporting Review Question 21 for the committee's consideration.

The committee considered the evidence presented and requested that the evidence statements be amended before drafting two recommendations.

#### 6. Next steps

The Chair thanked the committee for their time and contribution to Day 2. The venue, date and time of the next meeting was confirmed:

Date of next meeting: Monday 29 and Tuesday 30 January 2018.

Location of next meeting: NICE offices, Manchester.